Happy #NationalInternDay! At Tempest, our interns play an important role in our mission to advance cancer research and innovation. Their passion and fresh perspectives inspire us daily. We’re proud to be cultivating the next generation of scientists who may join the fight against cancer. Niklas Lamy – Biochemistry Intern Hayley Sperinde – Research Intern Josue Pizano – Chemistry Intern
About us
Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Brisbane, California
- Type
- Public Company
- Specialties
- Immuno-oncology
Locations
-
Primary
2000 Sierra Point Pkwy
Suite 400
Brisbane, California 94005, US
Employees at Tempest Therapeutics
Updates
-
Tempest President and CEO, Stephen Brady, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 4:00 p.m. ET. Listen to the live or archived presentation here: https://bit.ly/3k4pxZd
-
Tempest President and CEO, Stephen Brady, and CMO and Head of R&D, Sam Whiting MD PhD, will discuss the latest company updates in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Wednesday, May 29, 2024 at 2:00 p.m. ET. Watch the live or archived discussion here: https://bit.ly/3k4pxZd
Events | Tempest Therapeutics
ir.tempesttx.com
-
Tempest Therapeutics reposted this
Happy Administrative Professionals' Day! Today, we celebrate the incredible talent and dedication of our G&A teams in pursuit of bringing lifesaving drugs to cancer patients. Your contributions are invaluable. Thank you for all you do! #AdminProfessionalsDay
-
Happy Administrative Professionals' Day! Today, we celebrate the incredible talent and dedication of our G&A teams in pursuit of bringing lifesaving drugs to cancer patients. Your contributions are invaluable. Thank you for all you do! #AdminProfessionalsDay
-
This week we reported preclinical data at #AACR2024 demonstrating that TPST-1120 reduced tumor growth in kidney cancer as a monotherapy, as well as increased anti-cancer activity when combined with frontline chemotherapy and immunotherapy. These new data further support the clinical benefit observed in the TPST-1120 Phase 1 data presented in an oral presentation at ASCO 2022. Read more here: https://bit.ly/43OMwwH
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting | Tempest Therapeutics
ir.tempesttx.com
-
Today we announced that the journal Cancer Research Communications published positive data from the earlier phase 1 trial of TPST-1120 in advanced solid tumors. Data published demonstrated clinical activity of TPST-1120 as a monotherapy and in combination with nivolumab. Read more here: https://bit.ly/49jyaFv
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications | Tempest Therapeutics
ir.tempesttx.com
-
Yesterday we presented new preclinical data at the SITC 2024 Spring Scientific meeting showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors. Learn more about the data presented and the potential of TPST-1120 to treat multiple cancer types here: https://bit.ly/3v6sjpc
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types | Tempest Therapeutics
ir.tempesttx.com